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V ulnerability among cardiac patients is multi-factorial and may arise from myocardialinterstitial disease (e.g., ﬁbrosis or amyloid-
osis) or other derangements such as valve dysfunc-
tion, pulmonary hypertension, atherosclerosis, or
dysrhythmia. The multitude of pathways suggests a
need to employ cardiovascular imaging to identify
and characterize any lesions. This information then
enables the clinician to target the “correct” therapy
to the patient. This paradigm has been termed “preci-
sion medicine.”
Early observations regarding the signiﬁcance of
interstitial ﬁbrosis, including those by Weber and
Brilla (1) in animal models, along with clinical ad-
vances in human cardiac imaging, have combined to
focus attention on the entire range of myocardial
ﬁbrosis from focal to diffuse. Fibrosis associates with
capillary rarefaction, re-entrant arrhythmia, systolic
and diastolic dysfunction, and decreased perfusion
reserve (2,3). The latter 2 entities reverse with
regression of myocardial ﬁbrosis (4,5), supporting
ﬁbrosis as an important therapeutic target. Key
advances in cardiac magnetic resonance (CMR),
including pulse sequence development for T1 mea-
surement and mapping (6–9), histologic validation
in human hearts (10–15), and demonstration of
diagnostic (16,17) and prognostic (18–20) ability,
demonstrate the emerging utility of ﬁbrosis or inter-
stitial imaging in humans. Yet, further work*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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contents of this paper to disclose.undoubtedly remains along the road to demon-
strating clinical utility (21).In this issue of iJACC, Kammerlander et al. (22)
present a single-center, prospective, observational
cohort of 473 consecutive patients (without hyper-
trophic cardiomyopathy, amyloidosis, or Anderson-
Fabry disease) referred for CMR. Extracellular vol-
ume (ECV) was determined using myocardial and
blood T1 (pre- and post-gadolinium contrast, adjust-
ing for hematocrit), and its associations with both
histology and cardiovascular outcomes were charac-
terized. Of note, regions of interest excluded
myocardial infarction (MI), but included all other
myocardial areas, including those demonstrating
atypical late gadolinium enhancement. In the subset
of 36 patients who underwent left ventricular
myocardial biopsy and CMR, a moderate correlation
of r ¼ 0.493 (p ¼ 0.002), that is, r2 ¼ 0.24, was
observed, which was notably weaker compared with
prior investigations (10,11). During w13 months of
follow-up, 60 patients were hospitalized for heart
failure, acute coronary syndrome, pulmonary embo-
lism, or stroke; 11 died of cardiac causes. ECV asso-
ciated with outcome in univariable modeling, and
remained signiﬁcantly associated along with right
ventricular size in multivariable modeling of imaging
parameters (e.g., left atrial size, left ventricular ejec-
tion fraction [LVEF], etc.). However, when clinical
variables were added to multivariable regression,
ECV lost statistical signiﬁcance. In the ﬁnal model,
only age, atrial ﬁbrillation, coronary artery bypass
surgery, and right ventricular size remained associ-
ated with outcome.
These data do not dampen enthusiasm for ECV
and ﬁbrosis as relevant biomarkers and therapeutic
targets. Indeed, myocardial ﬁbrosis is only one
pathway among many that may confer vulnerability.
The ﬁndings of their ﬁnal models differ from those
reported from Pittsburgh (18), as well as a preliminary
report from Houston (23). We suspect that the patient
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25cohorts are fundamentally different. For example,
Kammerlander et al. (22) report that LVEF was not
signiﬁcantly associated with the combined endpoint
of cardiac hospitalization or death in either uni-
variable or multivariable models (whereas LVEF
remained signiﬁcant in the Pittsburgh cohort mor-
tality models). Among participants experiencing
events, median LVEF was 31% for patients from
Pittsburgh versus 63% for those from Vienna (Online
Supplementary Table 1 of the paper). Other signiﬁcant
differences in baseline comorbidities were present as
well. Given the robust prognostic data for LVEF in
most clinical populations, we suspect that regional
variation in CMR referral patterns may account for
some of the discrepant observations. In reviewing the
variables that remain in the ﬁnal model, we note that
atrial ﬁbrillation and coronary artery disease are
well-accepted pathways of morbidity and mortality.
These observations support the overall paradigm
that ﬁbrosis and other disease pathways confer
vulnerability.
Second, we wish brieﬂy to discuss methodology
for covariate selection for risk adjustment. Concep-
tually, one may choose variables based on prior
knowledge or standard, commonly accepted factors.
Alternatively, variable selection may focus on base-
line imbalances observed when stratifying by
outcome, and then creating multivariable models
using stepwise selection. In the Pittsburgh cohort, we
chose a limited number of fundamental variables
which are known to affect prognosis and which arewidely used in clinical practice given the number of
events. The utility of adding a large number of clin-
ical and imaging covariates to a stepwise selection
process may be useful for creating a prediction
model. However, if the overall purpose is to under-
stand how a novel imaging biomarker stands in
comparison to traditional and powerful markers of
cardiovascular risk, it may be reasonable to include
these variables in the ﬁnal models. Nonetheless, we
acknowledge a lack of agreement regarding stan-
dardized risk adjustment for particular outcomes, for
example, heart failure, and that further work and
consensus is needed.
We congratulate the authors for a meticulously
collected, prospective study of ECV and prognosis
with accompanying histological validation. We sup-
port their methodology for tracing all myocardial
regions outside of areas of any MI (if present), given
that the late gadolinium enhancement technique has
already been robustly validated for MI, but not for
quantifying non-MI ﬁbrosis. Their work, along with
ongoing other studies, supports the paradigm of
precision medicine and individualized care: employ-
ing imaging to match the correct therapy to the
right patient.
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